Health

Three reasons scientists are cautious about the Oxford coronavirus vaccine

Share
Three reasons scientists are cautious about the Oxford coronavirus vaccine

Research is taking place at an unprecedented scale - the world became aware of coronavirus at the beginning of the year, but already more than 20 vaccines are in clinical trials.

Scientists at Oxford University revealed that a vaccine being developed for the CCP virus, a novel coronavirus, has shown signs of immune response, according to the results of a clinical trial published on Monday.

The trial involving 1,077 healthy adult participants confirmed a single dose of the vaccine resulted in a four-fold increase in antibodies to the virus's spike protein in 95% of participants one month after injection.

On Monday German biotech company BioNTech and United States pharmaceutical company Pfizer said data from an early-stage trial of their experimental coronavirus vaccine showed that it prompted an immune response and was well-tolerated, similar to results seen in prior early test.

A coronavirus vaccine developed by the University of Oxford showed promising signs in making antibodies and triggering an immune response with patients.

The government already has a global licensing agreement with AstraZeneca and the University of Oxford to research, develop and manufacture a Covid-19 vaccine.

Compared with the control group of those given a meningitis vaccine, the COVID-19 vaccine caused minor side effects more frequently, according to the study.

The vaccine is safe, well-tolerated, and immunogenic.

The mRNA-1273 vaccine is being developed to prevent COVID-19 by producing antibodies to the virus.

"The immune system has two ways of finding and attacking pathogens, antibody and T cell responses", said Andrew Pollard, a member of the Oxford team.

The New York Times is reporting that two potential vaccines against the virus from Oxford University and the Chinese company CanSino have triggered immune responses in hundreds of humans without risky side effects. Of the participants, 253 received a high dose of the vaccine, 129 received a low dose, and 126 received a placebo.

Monday's positive results centred around immune response, but further testing is needed to see if the vaccine can effectively protect against infection.

While no vaccine candidate has yet been found to be effective and been approved for distribution, companies are planning ahead so as to be able to meet demand.

Share